cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Clinical trial NCT05025592 · UNKNOWN
Trial details
- NCT number
- NCT05025592
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-09-10
- Primary completion
- 2022-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.